Process Development and Scale-Up of PPAR α/γ Dual Agonist Lobeglitazone Sulfate (CKD-501)-Reference-Cited by-同舟云学术

Process Development and Scale-Up of PPAR α/γ Dual Agonist Lobeglitazone Sulfate (CKD-501)

Published:2007-01-20 Issue:2 Volume:11 Page:190-199
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Lee Hong Woo¹,Ahn Joong Bok¹,Kang Sung Kwon¹,Ahn Soon Kil¹,Ha Deok-Chan¹

Affiliation:

1. Process Research and Development Laboratory, Chemical Research Group, Chong Kun Dang Pharmaceutical Cooperation, Cheonan P. O. Box 74, Cheonan 330-831, South Korea, and Department of Chemistry, Korea University, 5-1-2, Anam-Dong, Seoul 136-701, Korea

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/op060087u

Reference34 articles.

1. Turner, N. C.; Clapham, J. C. InProgress in Drug Research; Jucker, E., Ed.; Virkhauser Verlag: Boston, Basel, 1998; pp 35−94.

2. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994

3. The role of PPARs in the transcriptional control of cellular processes

4. The PPARs: From Orphan Receptors to Drug Discovery

5. Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties;European Journal of Medicinal Chemistry;2024-09

2. Synthesis of Lobeglitazone intermediates seeking for continuous drug production in flow capillary microreactor;Journal of Industrial and Engineering Chemistry;2022-12

3. Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents;ChemMedChem;2022-10-26

4. A short review on synthetic strategies toward glitazone drugs;Synthetic Communications;2020-10-07

5. Efficacy and safety of lobeglitazone versus sitagliptin as an add‐on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks;Diabetes, Obesity and Metabolism;2020-06-18